India, Nov. 9 -- Vir Biotechnology, Inc. (VIR) is up 13.92 percent, gaining $1.70 to $13.91 on Monday. The stock advanced possibly after the company reported expanded Phase 2 SOLSTICE trial data showing promising results for its combination of elebsiran and tobevibart in adults with chronic hepatitis delta, the previous day. At Week 96, all 28 patients who completed combination therapy achieved undetectable levels of the virus.
Additionally, 89 percent of patients with paired liver stiffness measurements showed improved or stable results, with no study drug-related discontinuations or serious adverse events reported.
The stock is currently trading at $13.91, compared with the previous close of $12.21 on the Nasdaq. It opened at $13.18 and...